This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Cartier Esham
CSO at Biotechnology Innovation Organization
Speaker

Profile

Cartier Esham serves as Chief Scientific Officer and EVP of Emerging Companies at the Biotechnology Innovation Organization (BIO). In this role, Dr. Esham manages and directs BIO’s policy development, advocacy, research and educational initiatives for BIO’s emerging companies, which comprise approximately 90% of BIO’s membership. This includes capital formation policy and health policy impacting emerging companies, as well as research and analysis of the biopharmaceutical industry and life-science investment and financing.

Among the priorities of BIO’s Emerging Companies Section are: promoting a science-based FDA regulatory environment; supporting NIH funding and programs/initiatives such as SBIR and NCATS that promote the effective transfer of technology; and working to create a public and private market environment that incentivizes the research and development of innovative treatments and therapies.

Prior to joining BIO, Dr. Esham was a Vice President and Director of Research at Dutko Worldwide, a private consulting firm in Washington D.C., where she worked on a variety of environmental, education, science, technology, and health carerelated issues on the federal, state, and local levels. Dr. Esham has a Ph.D. in Microbiology from the University of Georgia, a master’s degree in Marine Biology from the University of North Carolina at Wilmington and a bachelor’s degree from the University of Kentucky. She has published papers in peer-reviewed scientific journals on water quality, marine microbial ecology, and bacterial phylogeny.


Agenda Sessions

  • Impact of the Inflation Reduction Act across the life science ecosystem

    15:00
  • Closing the gap: the imperative for women’s health in biopharma

    12:00

At this event